<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24411/0235-2990-2019-100045</article-id><article-id custom-type="elpub" pub-id-type="custom">antibiotics-156</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Анализ применения антисмысловых олигонуклеотидов для профилактики и лечения опасных и особо опасных вирусных инфекционных заболеваний</article-title><trans-title-group xml:lang="en"><trans-title>Analysis of Use of Antisense Oligonucleotides for Prevention and Treatment of Hazardous and Extremely Hazardous Viral Infectious Diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебедев</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedev</surname><given-names>V. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сизикова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Sizikova</surname><given-names>T. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плеханова</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Plekhanova</surname><given-names>T. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисевич</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisevich</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>48th Central Scientific Research Institute of the Ministry of Defense of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>06</day><month>05</month><year>2020</year></pub-date><volume>64</volume><issue>7-8</issue><fpage>56</fpage><lpage>62</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; ООО «Издательство ОКИ», 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">ООО «Издательство ОКИ»</copyright-holder><copyright-holder xml:lang="en">ООО «Издательство ОКИ»</copyright-holder><license xlink:href="https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/156">https://www.antibiotics-chemotherapy.ru/jour/article/view/156</self-uri><abstract><p>В обзоре рассмотрены различные поколения антисмыгсловык олигонуклеотидов (немодифицированные олигонуклеотиды, фосфоротиатные олигомеры, 2’-0-метил и 2’-0-метокси-этил модификации олигомеров, фосфородиамидат морфолиновые олигомеры и малые интерферирующие РНК), возможные механизмы их действия, их использование для профилактики и лечения опасных и особо опасных вирусных инфекционных заболеваний. При разработке средств экстренной профилактики и лечения опасных и особо опасных вирусных инфекционных заболеваний человека наиболее широкое применение нашли фосфородиамидат морфолиновые олигомеры и малые интерферирующие РНК. Сделан выход, что дальнейшее усовершенствование препаратов на основе антисмыгсловык олигонуклеотидов можно обеспечить путём улучшения структуры последних и поиска новых химических модификаций.</p></abstract><trans-abstract xml:lang="en"><p>The article describes different generations of antisense oligonucleotids (unmodified oligonucleotids, phosphorothioate oligomers, 2’-0-methyl and 2’-0-methoxy-ethyl modification of oligomers, phosphordiamidate morpholine oligomers and small interfering RNAs), the possible mechanism of their action, their use for prevention and treatment of hazardous and extremely hazardous viral infectious diseases. Phosphordiamidate morpholine oligomers and small interfering RNAs are most widely used in the development of emergency prevention and treatment of hazardous and extremely hazardous viral infectious diseases. The authors conclude, that further improvement of medications based on antisense oligonucleotids may be achieved by improving the structure of the latter and carrying out the search for new chemical modifications.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>антиемыеловые олигонуклеотиды</kwd><kwd>фосфородиамидат морфолиновые олигомеры</kwd><kwd>малые интерферирующие РНК</kwd><kwd>профилактика</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>antisense oligonucleotides</kwd><kwd>phosphordiamidate morpholine oligomers</kwd><kwd>small interfering RNAs</kwd><kwd>prevention</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
